The unprecedented length of the government shutdown has a lot of people scratching their heads about lots of things. From a personal perspective, I have heard that FDAers are still getting paid (Commissioned Corps and civil servants) but the unknown is, for how long? When will the user fee money really run out? Has FDA been able to use the money that they collected for the applications submitted between October 1, 2018 and the December 22, 2018 shutdown? It does not appear that OGD has furloughed any employees to date, but, again, for how long?
All big questions for sure and there are no clear answers. There are some other questions that seem to pop up; for instance, what happens to first-to-file ANDAs for NCE-1 products (there is one that has happened since the shutdown – see list below) and products for which there are newly listed patents in the Orange Book for which ANDA applicants are trying to be the first-to-file a Paragraph IV patent certification?
What is the 20-day window? Well, when an ANDA is submitted into the gateway, the sponsor has 20 days in which to assure that the user fee has been paid. Nothing would have been a concern if the shutdown lasted for only 20 days but now, Houston, we have a (potential) problem. ANDAs have been submitted to the electronic gateway and it appears that they may be just sitting in wait until the government opens. Other applicants may not know what to do and may have not submitted their ANDAs during the shutdown periods. This raises some interesting scenarios.
- FDA could reset all dates of submission dates to the first day the government opens. This seems fair since there are no clear guidelines on how to handle the 20-day window which has passed on many ANDAs that hit the gateway already.
- The FDA could start the 20-day window when the government shut down ends but give the applicants their original submission date to the gateway.
- FDA could say that, if the 20-day window since submission into the gateway has passed, they can’t file the ANDA! That seems a bit disingenuous, but due to the unprecedented nature of the length of the shutdown, policy will have to be made on the fly.
- If it appears that a new patent on a reference listed drug is filed, what happens to ANDAs that are submitted in an attempt to be first-to-file challenging the patent? It is not a problem for amendments or supplements to existing ANDAs because they are not user fee paying submissions, but a new ANDA hoping to challenge a new patent would be a fee paying ANDA and thus subject to the same questions that an NCE-1 would encounter. Do firms try to submit their ANDA into the gateway every day until the patent is published in the Orange Book, or will some other accommodation be made to account for this issue?
Are these all pie-in-the-sky, theoretical questions that have no impact? Well, for at least one product, SAVAYSA (EDOXABAN TOSYLATE) whose NCE-1 occurred on 1/8/19 (NCE expires 1/8/20), the day has come and gone. Still only 15 days have passed in the 20-day window, but it could be the first application to be impacted if the shutdown lingers on if an ANDA has been submitted.
Here are the other NCE-1 products appearing in the immediate line-up:
IBRANCE (PALBOCICLIB) NCE-1 date 2/3/19 – NCE expiration date 2/3/20
LENVIMA (LENVATINIB MESYLATE) NCE-1 date 2/13/19 – NCE expiration date 2/23/20
FARYDAK (PANOBINOSTAT LACTATE) NCE-1 date 2/23/19 – NCE expiration date 2/23/20
Hopefully, we can get a better look into how the FDA will make a decision on these issues before too long.